Search | Clinical Trials Finder

Conditions: Head and Neck Cancer, Stage I Hypopharyngeal Cancer, Stage I Laryngeal Cancer, Stage I Oropharyngeal Cancer, Stage II Hypopharyngeal Cancer, Stage II Laryngeal Cancer, Stage II Oropharyngeal Cancer, Stage III Hypopharyngeal Cancer, Stage III Laryngeal Cancer, Stage III Oropharyngeal Cancer, Stage IV Hypopharyngeal Cancer, Stage IV Laryngeal Cancer, Stage IV Oropharyngeal Cancer
Interventions: exercise intervention, questionnaire administration, quality-of-life assessment; Behavioral · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glioblastoma, Gliosarcoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide, Chloroquine, Tumor Treating Fields Therapy (TTF); Radiation · Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostate Adenocarcinoma
Interventions: Questionnaire; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Anxiety, Cancer
Interventions: Two Dimensional (2D) Informational Video, First-Person Virtual Reality Video, Third-Person Virtual Reality Video; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: 123-I-MIP-1072, 123-I-MIP-1095; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Durham, North Carolina

Conditions: Neurofibromatosis Type 2, Progressive Vestibular Schwannomas
Interventions: Bevacizumab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 6 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more

Conditions: Glioblastoma
Interventions: Lymphocyte harvesting & reinfusion; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasms
Interventions: Mammography and tomosynthesis imaging; Radiation
Lead sponsor: Duke University; Other
Eligibility: Female only
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Rectal Cancer
Interventions: Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic Neoplasms
Interventions: Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI); Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Phenylketonuria
Interventions: Preparative Radiation Therapy, Hepatocyte Transplant, Immunosuppression, Liver Evaluation, Neuro-psychological Assessment, Whole body Phe oxidation testing, Liver Biopsy; Radiation · Procedure · Drug + 3 more
Lead sponsor: Ira Fox; Other
Eligibility: 14 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Breast Cancer
Interventions: Radiation therapy, Study Drug; Radiation · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Scoliosis
Interventions: 3D topographical scan; Diagnostic Test
Lead sponsor: NSite Medical; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Palo Alto, California • Durham, North Carolina

Conditions: Cervical Cancer
Interventions: Treatment with Electronic Brachytherapy; Device
Lead sponsor: Xoft, Inc.; Industry
Eligibility: Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Pancreatic Cancer
Interventions: Directional Brachytherapy Source Implant; Device
Lead sponsor: CivaTech Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 6
States / cities: Tampa, Florida • Chicago, Illinois • Oak Lawn, Illinois + 3 more

Conditions: Prostate Cancer
Interventions: 1.5 T Elekta Unity MR-Linac system, Hydrogel rectal spacer (SpaceOAR); Radiation · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Dyskeratosis Congenita, Aplastic Anemia
Interventions: Campath 1H, Cyclophosphamide, Fludarabine, Total Body Irradiation, Stem Cell Transplantation, antithymocyte globulin, Methylprednisolone; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neoplasms, Malignant, Breast Neoplasm, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasm, Head and Neck Neoplasms
Interventions: Carlo Erba Ink Injection, EPR Oximetry Measurement; Device · Other
Lead sponsor: Philip Schaner; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 10 more

Conditions: Head and Neck Cancer
Interventions: Demographics questionnaires and the FACT HN questionnaire; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer
Interventions: pharmacological study, single photon emission computed tomography, iodine I 123 anti-CEA recombinant diabody T84.66; Other · Procedure · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Duarte, California

Conditions: Lysosomal Diseases, Gangliosidosis, GM1
Interventions: AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam; Biological · Procedure · Drug + 3 more
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: High Grade Glioma
Interventions: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy; Procedure · Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients

Radiotherapy Patient Education With Virtual Reality

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas

Early Detection of Breast Cancer Using Tomosynthesis Imaging

Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Liver Cell Transplant for Phenylketonuria

LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer

Study of 3D Scanning for Adolescent Scoliosis

Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

EPR Tumor Oximetry With CE India Ink

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study

Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

STARLITE for Unresectable High-Grade Gliomas